Truist Securities has maintained a Buy recommendation for Wintrust Financial (NASDAQ:WTFC), as reported on Thursday. The financial holding company, which boasts over $43 billion in...
An analyst from Truist Securities maintained Wintrust (NASDAQ: WTFC) at 'buy' with a price target of $86.00 from a prior price target of $92.00. Prior to this rating, Wintrust had 11 buy...
Wintrust Financial (NASDAQ:WTFC) Corporation (NASDAQ:WTFC), a robust lender, has demonstrated resilience in the face of high interest rates and waning loan demand that currently plague...
An analyst from Stephens maintained Wintrust (NASDAQ: WTFC) at 'overweight' with a price target of $92.00 from a prior price target of $90.00. Prior to this rating, Wintrust had 10 buy...
An analyst from UBS maintained Wintrust (NASDAQ: WTFC) at 'neutral' with a price target of $88.00 from a prior price target of $76.00. Prior to this rating, Wintrust had 11 buy ratings, 1...
An analyst from Truist Securities maintained Wintrust (NASDAQ: WTFC) at 'buy' with a price target of $92.00 from a prior price target of $80.00. Prior to this rating, Wintrust had 10 buy...
An analyst from DA Davidson maintained Wintrust (NASDAQ: WTFC) at 'buy' with a price target of $96.00 from a prior price target of $82.00. Prior to this rating, Wintrust had 11 buy...
An analyst from Raymond James maintained Wintrust (NASDAQ: WTFC) at 'strong buy' with a price target of $100.00 from a prior price target of $95.00. Prior to this rating, Wintrust had 11...
An analyst from RBC Capital maintained Wintrust (NASDAQ: WTFC) at 'outperform' with a price target of $100.00 from a prior price target of $94.00. Prior to this rating, Wintrust had 11 buy...
Investing.com - Wintrust (NASDAQ: WTFC) reported second quarter EPS of $2.38, $0.01 worse than the analyst estimate of $2.39. Revenue for the quarter came in at $560.57M versus the consensus...
An analyst from Jefferies maintained Wintrust (NASDAQ: WTFC) at 'buy' with a price target of $87.00 from a prior price target of $85.00. Prior to this rating, Wintrust had 10 buy ratings,...
Wintrust Financial (NASDAQ:WTFC) has filed mixed shelf of: Debt Securities, Common Stock, Preferred Stock, Depositary Shares, Warrants, Stock Purchase Contracts, Stock Purchase Units and...
An UBS analyst maintained Wintrust (NASDAQ: WTFC) at Neutral and a price target of $75.00 from a prior price target of $76.00. Prior to this rating, Wintrust had 11 buy ratings, 1 hold...
A Truist Securities analyst maintained Wintrust (NASDAQ: WTFC) at Buy and a price target of $80.00 from a prior price target of $87.00. Prior to this rating, Wintrust had 11 buy ratings,...
Investing.com - Wintrust (NASDAQ: WTFC) reported first quarter EPS of $2.80, $0.23 better than the analyst estimate of $2.57. Revenue for the quarter came in at $565.76M versus the consensus...
Here is your weekly roundup of the biggest news out of hedge funds and company top brass that you may have missed on InvestingPro. Sign up for real-time coverage of all the biggest corporate...
Wintrust Financial (WTFC) reported Q4 EPS of $2.23, $0.35 worse than the analyst estimate of $2.58. Revenue for the quarter came in at $550.7 million versus the consensus estimate of $553.61...
Investing.com - Wintrust (NASDAQ: WTFC) reported fourth quarter EPS of $2.23, $0.35 worse than the analyst estimate of $2.58. Revenue for the quarter came in at $550.7M versus the consensus...
Wintrust Financial (WTFC) reported Q3 EPS of $2.21, $0.18 better than the analyst estimate of $2.03. Revenue for the quarter came in at $502.93 million versus the consensus estimate of...
Investing.com - Wintrust reported on Tuesday third quarter {{erl-17579||earnings that beat analysts' forecasts and revenue that topped expectations. Wintrust announced earnings per share...
Wintrust Financial (NASDAQ:WTFC) reported Q2 EPS of $1.49, $0.20 worse than the analyst estimate of $1.69. Revenue for the quarter came in at $440.7 million versus the consensus estimate...
Pre-Open Stock Movers:Rigel (NASDAQ:RIGL) Pharmaceuticals, Inc. (Nasdaq: RIGL) 46% LOWER; announced top-line efficacy and safety data from the FORWARD Phase 3 clinical trial, a global,...
After-Hours Stock MoversDBV Technologies (Nasdaq: DBVT) 40% HIGHER; announced that its pivotal Phase 3 trial EPITOPE (EPIT in TOddlers with PEanut Allergy), assessing the safety and efficacy...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
